Her-2 involvement in osteosarcoma

Jonathan Gill, David S. Geller, Richard Gorlick

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The major goals of translational research in osteosarcoma entail the identification of prognostic factors and therapeutic targets. Given the relevance of epidermal growth factor receptor pathway to breast cancer and the fi nding that HER-2 was expressed in a proportion of osteosarcoma, it was reasonable to investigate this pathway further. Investigations of HER-2 in osteosarcoma have led to the publication of numerous confl icting reports with regard to the level and prognostic value of HER-2 expression, which are reviewed and discussed. Numerous lessons provided by this research experience are described. This pathway has also been explored as a therapeutic target with at least one study of trastuzumab for the treatment of osteosarcoma completed. Other studies utilizing alternative approaches to target the HER-2 receptor for the treatment of osteosarcoma have been considered.

Original languageEnglish (US)
Pages (from-to)161-177
Number of pages17
JournalAdvances in Experimental Medicine and Biology
Volume804
DOIs
StatePublished - 2014

Fingerprint

Osteosarcoma
Epidermal Growth Factor Receptor
Translational Medical Research
Publications
Breast Neoplasms
Therapeutics
Research
Trastuzumab

Keywords

  • Human epidermal growth factor receptor (HER-2)
  • Immunohistochemistry
  • Osteosarcoma
  • Targeted therapy
  • Trastuzumab

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Her-2 involvement in osteosarcoma. / Gill, Jonathan; Geller, David S.; Gorlick, Richard.

In: Advances in Experimental Medicine and Biology, Vol. 804, 2014, p. 161-177.

Research output: Contribution to journalArticle

Gill, Jonathan ; Geller, David S. ; Gorlick, Richard. / Her-2 involvement in osteosarcoma. In: Advances in Experimental Medicine and Biology. 2014 ; Vol. 804. pp. 161-177.
@article{fac798d8dcd24ecba767a0f671111d84,
title = "Her-2 involvement in osteosarcoma",
abstract = "The major goals of translational research in osteosarcoma entail the identification of prognostic factors and therapeutic targets. Given the relevance of epidermal growth factor receptor pathway to breast cancer and the fi nding that HER-2 was expressed in a proportion of osteosarcoma, it was reasonable to investigate this pathway further. Investigations of HER-2 in osteosarcoma have led to the publication of numerous confl icting reports with regard to the level and prognostic value of HER-2 expression, which are reviewed and discussed. Numerous lessons provided by this research experience are described. This pathway has also been explored as a therapeutic target with at least one study of trastuzumab for the treatment of osteosarcoma completed. Other studies utilizing alternative approaches to target the HER-2 receptor for the treatment of osteosarcoma have been considered.",
keywords = "Human epidermal growth factor receptor (HER-2), Immunohistochemistry, Osteosarcoma, Targeted therapy, Trastuzumab",
author = "Jonathan Gill and Geller, {David S.} and Richard Gorlick",
year = "2014",
doi = "10.1007/978-3-319-04843-7_9",
language = "English (US)",
volume = "804",
pages = "161--177",
journal = "Advances in Experimental Medicine and Biology",
issn = "0065-2598",
publisher = "Springer New York",

}

TY - JOUR

T1 - Her-2 involvement in osteosarcoma

AU - Gill, Jonathan

AU - Geller, David S.

AU - Gorlick, Richard

PY - 2014

Y1 - 2014

N2 - The major goals of translational research in osteosarcoma entail the identification of prognostic factors and therapeutic targets. Given the relevance of epidermal growth factor receptor pathway to breast cancer and the fi nding that HER-2 was expressed in a proportion of osteosarcoma, it was reasonable to investigate this pathway further. Investigations of HER-2 in osteosarcoma have led to the publication of numerous confl icting reports with regard to the level and prognostic value of HER-2 expression, which are reviewed and discussed. Numerous lessons provided by this research experience are described. This pathway has also been explored as a therapeutic target with at least one study of trastuzumab for the treatment of osteosarcoma completed. Other studies utilizing alternative approaches to target the HER-2 receptor for the treatment of osteosarcoma have been considered.

AB - The major goals of translational research in osteosarcoma entail the identification of prognostic factors and therapeutic targets. Given the relevance of epidermal growth factor receptor pathway to breast cancer and the fi nding that HER-2 was expressed in a proportion of osteosarcoma, it was reasonable to investigate this pathway further. Investigations of HER-2 in osteosarcoma have led to the publication of numerous confl icting reports with regard to the level and prognostic value of HER-2 expression, which are reviewed and discussed. Numerous lessons provided by this research experience are described. This pathway has also been explored as a therapeutic target with at least one study of trastuzumab for the treatment of osteosarcoma completed. Other studies utilizing alternative approaches to target the HER-2 receptor for the treatment of osteosarcoma have been considered.

KW - Human epidermal growth factor receptor (HER-2)

KW - Immunohistochemistry

KW - Osteosarcoma

KW - Targeted therapy

KW - Trastuzumab

UR - http://www.scopus.com/inward/record.url?scp=84907169734&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907169734&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-04843-7_9

DO - 10.1007/978-3-319-04843-7_9

M3 - Article

C2 - 24924174

AN - SCOPUS:84907169734

VL - 804

SP - 161

EP - 177

JO - Advances in Experimental Medicine and Biology

JF - Advances in Experimental Medicine and Biology

SN - 0065-2598

ER -